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Although  cytokines  are  normally  produced  by  peripheral 
immune cells, evidence in recent decades has also convincingly 
uncovered  their  production  from  CNS  glial  cells  (Buttini  and 
Boddeke, 1995). In particular, the immunocompetent, microglia, 
produce several cytokines and bear receptors for these immu-
notransmitters, which can act locally in an autocrine or paracrine 
manner to regular functioning of the original or neighboring cells, 
respectively (Benveniste, 1992).
Perhaps one of the most intriguing findings in recent years has 
been that cytokines can markedly affect neurotransmission within 
emotion regulatory brain circuits, and can induce hormonal changes 
akin to those normally observed following stressor exposure (Herman 
and Cullinan, 1997; Hayley et al., 2005). Moreover, numerous stud-
ies have implicated cytokines in the genesis of clinical depression 
and anxiety disorders. To this end, the current perspective review 
will focus upon evidence that neuro-immune interactions involv-
ing peripheral and glial derived cytokines play an important role in 
depression. Particular attention will be devoted to understanding the 
mechanisms through which inflammatory cytokines can affect brain 
processes to cause depressive symptoms and how novel treatment 
strategies could be developed based on these findings.
Inflammatory/Immune changes In depressIon
Owing to the intimate relationship between stressor exposure and 
the onset of depression, virtually all-animal models of the disorder 
involve administration of some degree of stress. In general, acute 
and chronic stressor exposure has been demonstrated to alter adap-
tive T and B lymphocyte proliferative responses and impair certain 
aspects of innate immunity, most notably NK cell activity (Maes, 
1999). Not surprisingly then, clinical depression is also associated 
with some degree of disturbed immunological responding, along 
with increased levels of prostaglandin and corticoid hormones, as 
well as complement and positive acute phase proteins (Miller et al., 
2002; Dantzer, 2006).
Background
It has become clear that cells of the immune system can affect 
the brain and a host of behavioral processes (Blalock, 1984). For 
instance, it is now accepted that circulating T lymphocytes and 
other peripheral immune cells routinely enter the central nerv-
ous system (CNS), albeit in limited concentrations, and perform a 
variety of “housekeeping” tasks that are essential for immunosur-
veillance. The converse is also true, psychological stressors (which 
induce neurotransmitter changes) have been demonstrated to dis-
turb functioning of cells of the adaptive immune system, including 
T and B lymphocytes, as well as innate immune cells, particularly 
natural killer (NK) cells and macrophages (Griffiths et al., 2000).
It should be underscored that the blood–brain barrier (BBB), as 
well as endogenous inhibitory and apoptotic mechanisms within the 
brain normally tightly regulate the flow of immune factors into and 
how long they persist within the brain. However, increasing evidence 
indicates that a range of neurological diseases, including multiple 
sclerosis, Alzheimer’s and Parkinson’s disease have a prominent neu-
roinflammatory component, involving some degree of immune cell 
infiltration, coupled with activation of brain glial cells (Cotter et al., 
1999; Czlonkowska et al., 2002; Wheeler and Owens, 2005).
In addition to the entry of immune cells into the brain paren-
chyma, substantial evidence has revealed that immune factors can 
influence CNS functioning through activation of receptors located 
on peripheral organs or the BBB (Goehler et al., 2006). Indeed, one 
of the primary mechanisms facilitating neuro-immune communi-
cation is the release of soluble low molecular weight glycoprotein 
messengers called cytokines. Cytokines can bind their receptors 
located on organs, such as the liver or spleen or the nodose gan-
glion and trigger the firing of neural fibers from these sites, which 
then signal the CNS (Cunningham and De Souza, 1993). Cytokines 
can also interact with BBB receptors to induce cyclooxygenase-2 
(COX-2) inflammatory signaling within the brain parenchyma 
(Rivest, 2001; Hayley et al., 2008).
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doi: 10.3389/fnbeh.2011.00019Although CNS cytokine elevations in depression could stem, in 
part, from peripheral sources, brain glia are also very likely con-
tributors. Along these lines, a reduction in the number of glia was 
apparent within the amygdala, anterior cingulate cortex (ACC) 
and PFC of individuals with major depression (Bowley et al., 
2002; Cotter et al., 2002). Further studies confirmed a reduction 
in expression of the astrocyte marker, GFAP, in postmortem brain 
tissue from depressed subjects (Webster et al., 2005). Parallel animal 
studies likewise revealed reductions in hippocampal GFAP follow-
ing stressor exposure that correlated with depressive-like behaviors 
(Liu et al., 2009). This is important in light of the fact that astro-
cytes are primary producers of the trophic factor, brain-derived 
neurotrophic factor (BDNF), which has also been reported to be 
reduced in the human depressed brain and in animal stressor mod-
els (Duman et al., 1999; Shirayama et al., 2002; Musazzi et al., 2009).
In contrast to the astrocyte reduction, an increased density of 
microglial cells was reported within the ACC and PFC of depressed 
individuals that committed suicide; yet, schizophrenic suicides also 
showed such an effect (Steiner et al., 2008). Hence, it might be 
some aspect of the suicidal behavior itself that contributed to the 
microgliosis. In fact, the profile of circulating cytokines was found 
to differ in suicide attempters compared to non-suicidal depressed 
patients, with the former group showing greater IL-6 and TNF-α 
elevations, coupled with IL-2 reductions (Janelidze et al., 2010). 
Nonetheless, it is informative that animal studies reported elevated 
microglial density and morphological changes following stressor 
exposure (Tynan et al., 2010). Ultimately, one could speculate that 
stressors favor diminished plasticity and neurochemical changes 
aligned with depressive pathology by reducing astrocyte trophic 
responses, while concomitantly augmenting microglial production 
of pro-inflammatory and oxidative factors.
cytokIne-stress Involvement and depressIon
When considering the involvement of cytokines in depression it 
is important to point out the likelihood that cytokines are impor-
tant for a subset but not all depressive symptoms. In this regard, 
cytokines have potent sickness inducing effects, which are often 
taken to reflect some form of depression (Anisman et al., 2008; 
Dantzer et al., 2008). While it is certainly reasonable that many 
aspects of sickness, such as the lethargy and “flu-like” symptoms, 
do resemble some of the more vegetative aspects of depression, the 
profound melancholia is harder to model in animals and might be 
somewhat independent from cytokine effects. Thus, it may be use-
ful to view cytokines as being only one potentially very important 
trigger that acts together with psychosocial challenges to provoke 
the manifestation and evolution of the disorder.
cytokIne-stress connectIon
Administration of IL-1β or TNF-α, typically engender an array 
of behavioral symptoms (soporific effects, ptosis, anorexia, fever, 
fatigue, reduced motor activity, curled body posture) referred to 
as “sickness behaviors” (Hayley et al., 1999; Dantzer et al., 2008). 
Similarly, these same cytokines also have potent activating effects 
on the hypothalamic–pituitary–adrenal (HPA) axis and promote 
increased  monoamine  utilization  in  numerous  brain  regions 
(Dunn, 2006; Anisman et al., 2008). Importantly, at least some of 
the behavioral consequences appear to be mediated, in part, by 
Pro-inflammatory cytokine release has been reported to be 
increased in stressed animals and in depressed individuals. Indeed, 
elevations of circulating interleukin-1β (IL-1β), IL-2, IL-6, and 
interferon-γ (IFN-γ) have reported in major depression (Maes,   
1999). However, some reported reductions of IL-2 production 
occurred with depression and were related to peripheral nore-
pinephrine levels but not depressed mood per se (Anisman et al., 
1999). Interestingly, dysthymia (chronic low grade depression) was 
actually associated with greater reductions in mitogen induced lym-
phocyte proliferation and elevations of circulating IL-1β compared 
to major depression (Anisman et al., 1999; Zaharia et al., 2000). 
Similarly, dysthymic children/adolescents were reported to dis-
play elevated IL-1β but reduced tumor necrosis factor-α (TNF-
α) plasma concentrations, whereas those with major depression 
showed no such changes (Brambilla et al., 2004).
There have been indications that the elevated systemic levels of 
IL-1β, IL-6, TNF-α, and IFN-γ normalized with anti-depressant 
administration (Basterzi et al., 2005; Tsao et al., 2006). Yet, the 
elevated production of IL-6, IL-10, and the soluble IL-6 receptor in 
severe depression (Sluzewska et al., 1995; Maes, 1999) and the ele-
vated IL-1β associated with dysthymia (Griffiths et al., 2000) were 
not attenuated with anti-depressant treatments. It might be the 
degree of clinical efficacy achieved that influences cytokine levels 
since elevated IL-6 and TNF-α plasma levels in depressed subjects 
diminished in parallel with a successful anti-depressant response 
(either with an SSRI or SNRI anti-depressant) (Yoshimura et al., 
2009). Further, elevations of cerebrospinal fluid IL-6 levels corre-
lated with depressive symptom severity (being most pronounced 
in suicide attempters (Lindqvist et al., 2009).
It  is  important  to  note  that  although  many  significant 
cytokine differences have been reported, substantial variability 
exists in cytokine levels normally apparent in clinical popula-
tions. Consequently, some researchers (e.g., Kubera et al., 2000; 
Huang and Lee, 2007) not surprisingly have failed to identify 
differences in cytokines that others report altered in depres-
sion (e.g., IL-1β). Yet, the pro-inflammatory cytokines, IL-1β, 
IL-6, and TNF-α have generally emerged from the literature 
as important players in depression. Indeed, one recent meta-
analysis that assessed 24 cytokine studies involving patients 
meeting DSM criteria for depression revealed elevated levels of 
IL-6 and TNF-α, yet levels of IL-1β, IL-2, IL-4, IL-8, IL-10, and 
IFN-γ were not significantly affected (Dowlati et al., 2010). A 
second meta-analysis further reported that IL-1β, IL-6, and the 
inflammatory marker, C-reactive protein (which is important in 
cardiac illness) were likewise positively associated with depres-
sion (Howren et al., 2009).
Although the data are particularly scant, a few recent postmor-
tem studies have assessed brain cytokine variations in depressed 
individuals that died from suicide. These have revealed some sta-
tistically significant (albeit modest) cytokine variations in stressor-
sensitive limbic brain regions. For instance, the mRNA for the type 
2 T helper cytokines, IL-4 and IL-13, were elevated in a gender-
dependent manner (IL-4 in females and IL-13 in males) in the 
orbitofrontal cortex of depressed suicides (Tonelli et al., 2008). 
Similarly, TNF-α was increased within the left hemisphere of the 
dorsolateral prefrontal cortex (PFC) of individuals that suffered 
from major depression (Dean et al., 2010).
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often used as a therapeutic treatment for certain cancers and hepatitis 
C, has been reported to cause a depressive syndrome (as well as irrita-
bility, anxiety, and cognitive problems) amenable to anti-depressant 
treatment (Denicoff et al., 1987; Dieperink et al., 2003; Constant 
et al., 2005; Raison et al., 2005). It is also important to note that the 
cancer and hepatitis C patients are undoubtedly under consider-
able emotional distress, and hence, the impact of IFN-α would be 
expected to be augmented by the concomitant stressor exposure, 
as we previously reported for mice exposed to the cytokine in the 
context of a psychosocial stressor (Anisman et al., 2007).
Animal studies revealed that rodents treated with IFN-α dis-
played marked signs of anhedonia, impaired hippocampal neuro-
genesis and a reduction of cortical neuronal fiber density (Kaneko 
et al., 2006; Ishikawa et al., 2007). Some studies also report that 
systemic IFN-α administration induced neurochemical changes 
(5-HT and NE in several brain regions) in rodents (Anisman et al., 
2007), as well as in rhesus monkeys (altered CSF DA metabolite, 
along with IL-6 and HPA hormones, coupled with reduced explora-
tion and huddling behaviors; Felger et al., 2007).
Many  anti-depressants,  including  fluoxetine,  trimipramine, 
and reboxetine, either suppress IFN-γ production or reduce the 
IFN-γ/IL-10 ratio (Diamond et al., 2006). Consistent with these 
findings, anti-depressant treatment was shown to normalize the 
otherwise high levels of IFN-γ expression observed in depressed 
patients (Kubera et al., 2001). Similarly, genetic knockout of the 
IFN-γ receptor prevented the depressive-like effects of Bacillus 
Calmette-Guerin infection in mice (a model of immune-mediated 
depression; O’Connor et al., 2009a).
The depressive-like effects of IFN-α as well as other pro-inflam-
matory cytokines, including IL-1β and IFN-γ, have been suggested 
to stem from the ability of these cytokines to affect the enzyme, 
indoleamine 2,3-dioxygenase (IDO), which is responsible for the 
catabolism of tryptophan to kynurenine (Hu et al., 1995; Menkes 
and MacDonald, 2000; Capuron et al., 2003; O’Connor et al., 
2009b). Essentially, tryptophan can be metabolized to 5-HT or be 
affected sequentially by the enzymes, ATP bind cassette and IDO, 
resulting in the production of kynurenine, which can further fol-
low two different metabolic routes resulting in production of: (1) 
the NMDA antagonist, kynurenic acid, or (2) the potentially toxic 
metabolites, 3-hydroxykynurenine and quinolinic acid.
The potential importance of the tryptophan–kynurenine path-
way in depression was first proposed by Mangoni (1974) and later 
expanded upon by Myint and Kim (2003) with subsequent in vitro and 
in vivo experiments demonstrated that IFN-α did alter IDO activity 
and reduce 5-HT levels (Myint et al., 2007). In fact, reduced tryp-
tophan and increased levels of toxic kynurenine metabolites correlated 
with the depressive symptoms observed in hepatitis C patients treated 
with IFN-α (Bonaccorso et al., 2002; Raison et al., 2010). Besides being 
increased with depression, these kynurenine metabolites (3-hydrox-
ykynurenine and quinolinic acid) have neurotoxic effects and have 
been reported to synergistically induce free radicals in several neu-
rodegenerative diseases (Wichers and Maes, 2004; Hartai et al., 2005; 
Wichers et al., 2005). Ultimately, an imbalance in tryptophan metabo-
lism that favors activation of the kynurenine–quinolinc acid pathway 
could foster depressive pathology through: (1) a reduction in available 
5-HT and (2)   accumulation of toxic metabolites.
central mechanisms, as low doses of IL-1β or TNF-α administered 
directly into the brain elicited these behaviors (Maier et al., 1999; 
Konsman et al., 2002). The behavioral and neurochemical impact 
of IL-6, although similar in profile, is somewhat less pronounced 
than that of IL-1β or TNF-α (Dunn et al., 1999; Brebner et al., 2000; 
Hayley et al., 2005). However, the cytokine normally requires its 
endogenous soluble receptor ligand for its full range of biological 
effects (in contrast to the endogenous IL-1β and TNF-α soluble 
antagonists, the IL-6 soluble receptor acts as an agonist) and hence, 
exogenous IL-6 alone might have moderate CNS effects.
It is highly likely that the effects of cytokines are intermingled 
with the impact of the daily stressors that one normally faces. In 
this regard, it is important to note that social stressors were reported 
to augment the impact of immunological challenges on CNS func-
tioning (Avitsur et al., 2005; Gibb et al., 2008). For instance, we 
previously found that when mice were subjected to a psychosocial 
stressor (disruption of social housing), they displayed greatly aug-
mented behavioral changes and HPA activation to concomitant 
or subsequent immune (LPS, poly I:C) or cytokine (interferon-α) 
challenge (Anisman et al., 2007; Gandhi et al., 2007; Gibb et al., 
2008). Interestingly, the bacterial mimic, LPS, but not the viral 
analog, poly I:C, synergistically increased the impact of the social 
stressor upon sickness and plasma corticosterone levels. Moreover, 
LPS also interacted with the social stress to additively or synergisti-
cally enhance CNS mRNA for the cytokines IL-6, IL-10, and TNF-α 
(in a brain region and cytokine specific manner; Gibb et al., 2011).
The fact that many of the CNS effects of cytokine and stres-
sor exposure were strain-dependent is of importance given that 
genetic vulnerability likely contributes to stressor sensitivity and 
hence, depressive illness. Indeed, the behavioral and HPA varia-
tions induced by stressor + LPS treatments appeared to be more 
pronounced in BALB/cByJ mice (which were previously reported 
to be a “stressor sensitive” strain), compared to the more “stres-
sor hardy” C57BL/6ByJ strain (Gibb et al., 2011). Yet, the fact that 
elevations in circulating and central cytokines were greater in the 
C57BL/6ByJ strain suggests that the role of genetics and cytokine 
signaling is probably quite complex.
In terms of potential signaling CNS pathways that might subserve 
the common effects of cytokines and stressors, recent studies have 
revealed that IL-1β and its downstream transcription factor, NFkB, 
are important mediators of the anti-neurogenic and depressive-like 
effects of acute and chronic stressor exposure. Specifically, pharma-
cological or genetic inhibition of either IL-1β or NFkB prevented the 
depressive-like behavioral changes (reduced mobility in a forced swim 
test and reduced consumption of a sucrose solution) and reduction 
of hippocampal neurogenesis normally provoked by acute restraint 
or repeated exposure a series of different mild stressors (Koo and 
Duman, 2008; Koo et al., 2010). Interestingly, NFκB mediated signal-
ing following Toll-like receptor (TLR) activation was also reported to 
be influenced by psychosocial stressors (Bailey et al., 2007), raising the 
possibility that this signaling pathway might be especially sensitive to 
the impact of both immune and psychological challenges.
Interferons
Given their potent anti-viral and anti-tumor effects that have resulted 
in widespread clinical use, coupled with their numerous CNS effects, 
IFNs might be particularly important with regards to neuropsychi-
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related  hematopoietic  cytokines,  including  granulocyte  colony 
stimulating factor, might act, in part, through their ability to induce 
BDNF expression within the CNS.
Central infusion of BDNF (considered a neurotrophic cytokine 
itself) was shown to induce an anti-depressant-like effect while 
concomitantly  promoting  sprouting  of  central  5-HT  neurons 
(Altar, 1999). Likewise, hippocampal infusion of BDNF produced 
anti-depressant-like effects in the learned helplessness and forced 
swim models of depression (Shirayama et al., 2002). As would be 
expected, several clinically beneficial treatments, including SSRIs, 
tricyclics, and electroconvulsive therapy, increased hippocampal 
BDNF expression (Shirayama et al., 2002; Castrén et al., 2007) and 
the reduced BDNF associated with restraint stress was prevented 
by anti-depressant treatment (Duman et al., 1999).
Finally, one promising approach to treating the inflammatory 
aspects of depression is the use of specific cytokine antagonists. In 
this regard, most evidence would favor targeting IL-1β using the 
endogenous IL-1β receptor antagonist, IL-1ra. Indeed, IL-1ra was 
reported in several studies to prevent the development of depres-
sive-like behavioral and neurochemical pathology, as well as the 
reduction of hippocampal neurogenesis that was induced by chronic 
stressor exposure (Koo and Duman, 2008; Norman et al., 2010).
conclusIons and future dIrectIons
This review discusses the evidence for involvement of cytokines and 
their inflammatory signaling components in clinical depression. It is 
posited that normalization of some of the pro-inflammatory aspects 
of  depression  would  have  beneficial  clinical  effects.  Hence,  anti-
inflammatory agents (e.g., those affecting COX-2 and IDO or target-
ing specific cytokines, such as IL-1β) could hold therapeutic potential 
as add-on or adjunct treatment with more traditional anti-depressant 
strategies. At the same time, novel cytokines with neurotrophic con-
sequences, particularly BDNF, appear attractive. Indeed, mounting 
data indicate structural and neuroplastic (e.g., reduced hippocampal 
volume and neurogenesis) disturbances may occur in depression.
Whatever the case, it is being increasingly recognized that depres-
sion is a spectrum disorder with several endophenotypes, which are 
likely characterized by specific differences in their neurochemistry 
and underlying inflammatory immunological changes. Hence, first 
recognizing the nature of immune and cytokine changes in these 
depressive subtypes is necessary in order to tailor specific interven-
tions. Once brought to the clinical arena, several practical issues 
require addressing including, bioavailability and CNS penetration 
of the agents (as cytokines typically do not readily cross the BBB), as 
well as consideration of the possibility that manipulation of immu-
nity could have drastically undesirable consequences (e.g., increased 
infection or tumor production). In effect, further data are required to 
more completely understand the critical inflammatory components 
to be targeted and the long-term consequences of their manipulation.
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toward an antI-Inflammatory/neurotrophIc 
treatment strategy
Many broad-spectrum anti-inflammatory agents presently are avail-
able for a controlling fever, pain, and edema for a range of peripheral 
immune related conditions. Importantly, many of these compounds 
have also been shown to have beneficial CNS effects, including hav-
ing neuroprotective effects in animal models of cerebral stroke, 
Alzheimer’s and Parkinson’s disease (Teismann et al., 2003; Phillis 
et al., 2006). Moreover, some scattered preclinical and stressor-based 
animal studies suggest that non-steroidal anti-inflammatory drugs 
(NSAIDS), including aspirin, ibuprofen, celecoxib, and naproxen 
might possibly have some anti-depressant properties (Müller et al., 
2006; Müller and Schwarz, 2008). These drugs typically work by 
blocking cyclooxygenases, which of course are the rate-limiting 
enzymes (COX-1, -2, and -3 present in the CNS) in prostaglandin 
synthesis. COX-2 is subject to induction by a variety of inflamma-
tory stimuli, many of which (e.g., cytokines) have been implicated 
in the generalized activation of microglial cells in response to and 
as a corollary of brain injury and infection (Hayley et al., 2008).
One recent study found that celecoxib alleviated the depressive-
like behaviors and prevented the COX-2 elevations associated with 
21 days of chronic stress (Guo et al., 2009). Similarly, administration of 
celecoxib augmented the clinical impact of the anti-depressant, fluox-
etine (Akhondzadeh et al., 2009). This important finding suggests 
the possibility that anti-inflammatory drugs might be useful adjunct 
or “add-on” treatments, which could act additively or synergistically 
with SSRI or SNRI anti-depressants to bolster the clinical efficacy.
Mechanistically, NSAIDs could contribute anti-depressant-like 
effects by blocking COX-2 activity, since this inflammatory enzyme, 
along with its associated products, prostaglandins and kynurenine, 
have been associated with depression (Müller and Schwarz, 2008). 
Moreover, the immune alterations that likely occur with depression 
have been reported to alter tryptophan/kynurenine metabolism, 
favoring the neurotoxic effects of quinolinic acid (Wichers and 
Maes, 2004). Of course, the possibility exists that COX-signaling 
could also influence depressive symptoms by affecting hormonal 
activity. Indeed, aspirin was reported to reduce waking cortisol lev-
els and improve memory in depressed subjects (Watson et al., 2009).
Another compound of significance is the tetracycline antibiotic, 
minocycline, which has potent anti-inflammatory effects (includ-
ing a suppression of microglial activity) that are independent of 
its antimicrobial actions (Pae et al., 2008). Recently, brain infu-
sion (into the nucleus accumbens) or systemic administration of 
minocycline was shown to impart anti-depressive-like effects in 
the forced swim test. Moreover, co-administration of minocycline 
with the SSRI anti-depressant, fluoxetine, induced a synergistic 
anti-depressive effect (Molina-Hernández et al., 2008a,b). The anti-
depressive effects of minocycline could stem from its ability to 
block IDO activity, resulting in a normalization of the kynurenine/
tryptophan ratio (Myint et al., 2007).
In addition to broad-spectrum pharmacological agents, spe-
cific cytokines with anti-inflammatory or neurotrophic properties 
have been suggested to have clinical anti-depressant properties. 
For instance, erythropoietin is a cytokine produced predominately 
by the kidney, which, besides directing the trafficking of immune 
cells and having anti-apoptotic actions, was reported to provoke 
anti-depressant-like effects in the forced swim and novelty induced 
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